📖 Your Q2 Earnings Guide: Discover the Stocks ProPicks AI Highlights to Jump Post-EarningsRead more

Marathon Partners urges Dr Martens to buy back stock, detail expense cuts

Published 05/20/2024, 04:26 PM
Updated 05/20/2024, 05:31 PM
© Reuters. FILE PHOTO: Dr. Martens shoes are displayed inside a shop in Manchester, Britain, May 26, 2023. REUTERS/Jason Cairnduff/File photo

By Svea Herbst-Bayliss

BOSTON (Reuters) -Investment firm Marathon Partners Equity Management is turning up the heat on Dr Martens by urging the British boot maker to detail planned expense cuts and to buy back stock, people familiar with the matter told Reuters.

The increased pressure comes roughly two months after Marathon Partners' managing member Mario Cibelli suggested Dr Martens launch a strategic review that could lead to its sale, arguing it was the best way forward for the company, whose chunky lace-up boots have been a fashion statement since the 1960s.

Cibelli has told executives it would be sensible for Dr Martens to lay out specific plans when it announces earnings on May 30, which are expected to be in line with previously issued guidance, the sources said.

A representative for Dr Martens declined to comment.

Last month the stock price hit a record low of 65.50 pence as the company forecast revenue in the key U.S. market would drop by double digits this year. Dr Martens' share price has dropped 81% since its public listing in 2021.

On Monday, trading in London closed little changed at 85 pence. Shares closed U.S. trading up 4.6% at $1.13.

Cibelli argued the company's intrinsic value remains intact, but that management should seize on the lower share price to buy back stock now, the sources said.

The timing could be especially attractive now that Dr Martens is poised to start generating significant free cash flow.

Cibelli believes that the company may be able to generate approximately $750 million of cumulative free cash flow over the next three years as modest growth resumes, some cost savings are realized and excess inventory is reduced to normal levels, said one of the sources who is familiar with his thinking.

The sources asked to remain anonymous because they were not permitted to comment publicly on the private discussions.

At the same time, Cibelli told executives that investors are owed specifics about the company's cost cutting program, especially in the wake of the company's lowered profitability estimates.

Marathon Partners owns roughly 5 million shares in Dr Martens, making it one of its 30 largest investors.

In light of the company's current market value of about $1 billion, Cibelli said earlier this year that the company's exceptionally strong brand could make it attractive to potential buyers who might be willing to spend at least $2 billion to acquire it.

Under U.K. rules, Dr Martens would have to announce a formal offer to the company.

Dr Martens' new chief financial officer, Giles Wilson, whose appointment was announced last year, joined this month.

© Reuters. FILE PHOTO: Dr. Martens shoes are displayed inside a shop in Manchester, Britain, May 26, 2023. REUTERS/Jason Cairnduff/File photo

CEO Kenny Wilson, whose departure has been announced, is expected to leave the company by the end of the fiscal year on March 31, the company said previously. The two executives are not related.

Dr Martens was bought by private equity firm Permira in 2014 and in 2021, it was listed publicly. Permira still owns roughly 38.5% of Dr Martens.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.